The ReMissions, Moffitt’s house band, rocked the stage tonight at Sparkman Wharf! 🎶 Our head and neck team offered free cancer screenings, and the Miles for Moffitt crew handed out race-day swag. It was an incredible night of music, community and raising awards for cancer

Crisp, tangy and packed with antioxidants! 🍎 Nutrition researcher Join Sylvia Crowder, PhD, (Sylvia Crowder) shares a Brussels sprout apple slaw that makes the perfect fall dish.

Why is breast density important when it comes to breast cancer screening? In this second video of our Breast Cancer Awareness Month series, Dr. Dana Ataya, breast radiologist at Moffitt Cancer Center, breaks down what breast density means, why it matters, and how it can impact early

I'm gonna finish this PhD. I'm gonna finish this PhD. I'm gonna finish this PhD. I'm gonna finish this PhD. I'm gonna finish this PhD. *screams for two hours, takes a deep breath* I'm gonna finish this PhD. I'm gonna finish this PhD. I'm gonna finish this PhD. I'm gonna finish-

From feel-good music to free cancer screenings, The ReMissions, Moffitt's house band, kept the good vibes going at Sparkman Wharf! 💙 Thank you to everyone who stopped by to celebrate hope, connection and community.

x.com/i/article/1981…

At the AACR-NCI-EORTC annual meeting, Bruna Pellini, MD (Bruna Pellini, MD), presents preclinical findings on combining antibody-drug conjugates (ADCs) with targeted therapies for lung cancer patients. #Targets25

This afternoon, Sandy & Kristin officially kick off the 2nd biannual Mathematical Oncology meeting in beautiful St Pete Beach!

Next up is former student, friend and IMO member now a fellowship awardee working in London Imperial College London & The ICR, Maximilian Strobl presenting "Bridging the gap: What pre-clinical experiments can teach us about math model-guided treatment scheduling" #mathonco25

🧬 #DYNAMICIII Trial published in Nature Medicine ctDNA-guided adjuvant therapy in stage III colon cancer: Summary of DYNAMIC-III Trial Findings (ASCO & ESMO 2025) 🔹 For ctDNA-negative patients (post-surgery): 3-year RFS was high (~87%), confirming a low recurrence risk.

Closing this first session on digital twins is MD Anderson Cancer Center Heiko Enderling lab member Pirmin Schlicke: "Calibrating Tumor Dynamics from Single-Timepoint Biopsy Data" #mathonco25 He didn’t want to share most of the talk!

x.com/i/article/1981…

Advance your career in #CancerResearch with the Moffitt Cancer PhD program! Application deadline: December 1, 2025 Are you passionate about fighting cancer? Our program prepares future scientists with a rigorous curriculum and offers four unique majors: • Cancer Biology •

Next up is Pamela Jackson: "Sex-distinct transcriptomic signatures underlie MRI-defined edema patterns in human gliomas" #MathOnco25 Cedars-Sinai

Demi Busatta, Chair of the House Higher Education Budget Subcommittee, visited Dr. Patrick Hwu's lab and the Population Engagement and Research Lab (PEARL) to see firsthand how state support and investment drive Moffitt’s research, education, and innovation efforts.🧬

Closing this session is Noemi Andor lab member Vural Tagal presenting "Modeling karyotype-driven adaptations to metabolic restrictions predict therapeutic response and immunogenicity in cancers" #MathOnco25 IMO Moffitt Cancer Center

Our opening plenary presentation for day 2 is by Galit Lahav from Harvard Medical School presenting, "Information Transfer through Protein Dynamics" #MathOnco25

This week at #MathOnco25, researchers are coming together to advance the field of mathematical oncology. This year's conference highlights evolutionary therapy, hosted by Sandy Anderson, PhD (Sandy Anderson) and supported by the Center of Excellence for Evolutionary Therapy.

AI is everywhere, including in cancer research labs. I had a great conversation with Kennady Bullock (Kennady B) from my lab at Moffitt Cancer Center about how we’re using artificial intelligence (AI) to train T cells to better recognize and attack cancer. 🎥 Watch now to learn how

ctDNA-Guided Adjuvant Immunotherapy Sets a New Standard in #BladderCancer 🧬 The phase III IMvigor011 (NEJM 2025) showed that ctDNA-guided adjuvant atezolizumab significantly improved outcomes in ctDNA⁺ muscle-invasive bladder cancer: 🔹 DFS: 9.9 vs 4.8 mo (HR 0.64, p=0.005)